This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics
by Zacks Equity Research
Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.
LLYPositive Net Change TMDXNegative Net Change HIMSNegative Net Change IONQPositive Net Change
computers medical medical-devices pharmaceuticals
Top Stock Reports for Broadcom, Philip Morris & Novo Nordisk
by Mark Vickery
Broadcom, Philip Morris, and Novo Nordisk face contrasting outlooks as AI growth, smoke-free expansion, and obesity drug hurdles shape performance.
NVONegative Net Change PMPositive Net Change CMINegative Net Change AVGOPositive Net Change HCAPositive Net Change SONYNegative Net Change
consumer-staples medical pharmaceuticals semiconductor
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
by Kinjel Shah
Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.
AZNPositive Net Change BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
by Ethan Feller
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts
JNJPositive Net Change LLYPositive Net Change CRMDNegative Net Change
biotechnology medical medical-devices pharmaceuticals
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
by Ahan Chakraborty
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
by Ekta Bagri
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
by Ekta Bagri
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
NVSPositive Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Bank of America, Roche, Intuit and TSS
by Zacks Equity Research
BAC, RHHBY, INTU and TSSI post varied growth stories, from AI-driven expansion to drug pipeline gains and digital revenue momentum.
BACNegative Net Change RHHBYPositive Net Change INTUNegative Net Change TSSINegative Net Change
computers construction finance pharmaceuticals
Top Research Reports for Bank of America, Roche & Intuit
by Mark Vickery
Zacks highlights research on Bank of America, Roche, Intuit, and microcap TSS, noting growth opportunities despite mixed industry trends.
BACNegative Net Change RHHBYPositive Net Change CNINegative Net Change INTUNegative Net Change NXPINegative Net Change TSSINegative Net Change VRTNegative Net Change
computers construction finance pharmaceuticals
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly
by Santanu Roy
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change
pharmaceuticals
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
CRMDNegative Net Change ZYMENegative Net Change IMVTPositive Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
NBIXPositive Net Change CRMDNegative Net Change XENEPositive Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
by Zacks Equity Research
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
BIIBPositive Net Change BAYRYNegative Net Change CRMDNegative Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?
by Kinjel Shah
Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.
BSXPositive Net Change JNJPositive Net Change MDTPositive Net Change SYKNegative Net Change
pharmaceuticals
2 Outperform Rated Small Caps with Recent Pull-backs
by Mark Zinski
ELTP and TSSI are growth stories with recent material pull-backs.
ELTPPositive Net Change TSSINegative Net Change
artificial-intelligence pharmaceuticals
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
by Zacks Equity Research
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change VRNAPositive Net Change
pharmaceuticals
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
by Ahan Chakraborty
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
by Kinjel Shah
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
MRKPositive Net Change MRNAPositive Net Change SMMTPositive Net Change VRNAPositive Net Change
pharmaceuticals
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?
by Kinjel Shah
Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change
pharmaceuticals
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Ekta Bagri
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
GILDNegative Net Change INOPositive Net Change DERMNegative Net Change ZVRAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
by Santanu Roy
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.
GSNegative Net Change JNJPositive Net Change SBUXPositive Net Change INTUNegative Net Change MTDNegative Net Change APAMNegative Net Change SHOPNegative Net Change NOBLNegative Net Change NTLAPositive Net Change RFILNegative Net Change FHINegative Net Change DGXXPositive Net Change
business-services computers finance internet medical medical-devices pharmaceuticals restaurants semiconductor
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
by Zacks Equity Research
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
REGNNegative Net Change CRMDNegative Net Change NTLAPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings gene-therapy medical pharmaceuticals
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
by Zacks Equity Research
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
GSKNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Stock Market News for Aug 8, 2025
by Zacks Equity Research
U.S. stocks ended mixed on Thursday, with the Dow and the S&P 500 giving up their gains, as investors assessed President Donald Trump's plans to impose hefty tariffs on chip imports and digested the latest batch of corporate earnings.
AAPLNegative Net Change AMDNegative Net Change CATNegative Net Change LLYPositive Net Change
industrial-products pharmaceuticals semiconductor tech-stocks
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
by Zacks Equity Research
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
pharmaceuticals